Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011853 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Yuqi Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvan…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, HIV-1, HIV Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Engineered T cells hold great promise to become part of an effective HIV cure strategy, but it is currently unclear how best to redirect T cells to target HIV. To gain insight, we generated engineered T cells using lentiviral vectors encoding one of three distinct HIV-specific T cell receptors (TCRs) or a previously optimized HIV-targeting chimeric antigen receptor (CAR) and compared their functional capabilities. All engineered T cells had robust, antigen-specific polyfunctional cytokine profiles when mixed with artificial antigen-presenting cells. However, only the CAR T cells could potently control HIV replication. TCR affinity enhancement did not augment HIV control but did allow TCR T cells to recognize common HIV escape variants. Interestingly, either altering Nef activity or adding additional target epitopes into the HIV genome bolstered TCR T cell anti-HIV activity, but CAR T cells remained superior in their ability to control HIV replication. To better understand why CAR T cells control HIV replication better than TCR T cells, we performed a time course to determine when HIV-specific T cells were first able to activate Caspase 3 in HIV-infected targets. We demonstrated that CAR T cells recognized and killed HIV-infected targets more rapidly than TCR T cells, which correlates with their ability to control HIV replication. These studies suggest that the speed of target recognition and killing is a key determinant of whether engineered T cell therapies will be effective against infectious diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
- Adaptimmune Ltd, Abingdon, United Kingdom.
- Immunocore Ltd., Abingdon, United Kingdom.
ORCID-Profile: James L Riley
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Institute of Allergy and Infectious Diseases
- Adaptimmune
Zitieren
APA
Zhou, Y., Jadlowsky, J., Baiduc, C., Klattenhoff, A. W., Chen, Z., Bennett, A. D., Pumphrey, N. J., Jakobsen, B. K., & Riley, J. L. (2023). Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011853
Vancouver
Zhou Y, Jadlowsky J, Baiduc C, Klattenhoff AW, Chen Z, Bennett AD, et al. Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011853
BibTeX
@article{Zhou2023,
author = {Zhou, Yuqi and Jadlowsky, Julie and Baiduc, Caitlin and Klattenhoff, Alex W and Chen, Zhilin and Bennett, Alan D and Pumphrey, Nicholas J and Jakobsen, Bent K and Riley, James L},
title = {Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011853}
}
EUVIMED